FAM13B: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: FAM13B

NCBI ID: G51306

FAM13B

FAM13B: A Promising Drug Target and Biomarker for Chronic Pain Management

Abstract:

FAM13B is a protein that has been identified as a potential drug target and biomarker for the management of chronic pain. It is a member of the FAM13 family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and apoptosis. This protein has been shown to play a crucial role in the regulation of pain perception and the modulation of pain signals.

The discovery of FAM13B as a potential drug target and biomarker for chronic pain management has significant implications for the treatment of chronic pain conditions, such as osteoarthritis, rheumatoid arthritis, and cancer-related pain. By targeting this protein, scientists and healthcare professionals may be able to develop new, more effective treatments for these debilitating conditions.

FAM13B: A Protein Implicated in Pain Signaling

FAM13B is a member of the FAM13 family, which is characterized by the presence of a unique domain called the FAM13B protein. This domain is known to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and apoptosis.

One of the key functions of FAM13B is its role in the regulation of pain perception and the modulation of pain signals. Pain signals are generated by the body's sensors,

Protein Name: Family With Sequence Similarity 13 Member B

The "FAM13B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM13B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets